Keurig Dr Pepper To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…
Relmada Therapeutics And 2 Other Penny Stocks Insiders Are Buying
The Dow Jones index closed lower by more than 300 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session
Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.<
12 Health Care Stocks Moving In Thursday’s Intraday Session
Gainers Omega Therapeutics (NASDAQ:OMGA) shares increased by 99.6% to $5.45 during Thursday’s regular session. The market value of…
Earnings Scheduled For November 8, 2023
Companies Reporting Before The Bell
• Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.
Earnings Outlook For Relmada Therapeutics
Relmada Therapeutics (NASDAQ:RLMD) is set to give its latest quarterly earnings report on Wednesday, 2023-11-08. Here’s what investors…
Relmada Therapeutics To Present New Preclinical Data On Its Psilocybin Program At AASLD The Liver Meeting 2023
Low-dose psilocybin generated statistically significant reductions in liver fat content, plasma glucose levels and body weight gain in a mice model with high-fat-high-fructose diet (HFHFD)-induced metabolic
12 Health Care Stocks Moving In Thursday’s Pre-Market Session
Gainers Applied Molecular (NASDAQ:AMTI) stock moved upwards by 49.2% to $0.31 during Thursday’s pre-market session. The company’s market…
Relmada Therapeutics’ Lead Candidate Shows Promise In Pivotal Depression Study
Relmada Therapeutics Inc (NASDAQ: RLMD) announced efficacy results for the de novo (or new to treatment) patients (204 patients) and safety results for all subjects (627 patients) from the Phase 3 trial (Study 310) of REL-1017 in patients with
Relmada Therapeutics Announces Efficacy And Safety Results From The Phase 3 Long-Term Study Of REL-1017 In Major Depressive Disorder
Patients newly treated with REL-1017 for up to one year experienced rapid, clinically meaningful, and sustained improvements in depressive symptoms and associated functional impairmentLong-term dosing with REL-1017 was